MedPath

Implementing the NYU Electronic Patient Visit Assessment (ePVA) for Head and Neck Cancer In Rural and Urban Populations

Not Applicable
Recruiting
Conditions
Head and Neck Cancer
Interventions
Behavioral: NYU Electronic Patient Visit Assessment (ePVA)
Behavioral: Usual Care
Registration Number
NCT06030011
Lead Sponsor
The University of Texas Health Science Center, Houston
Brief Summary

The PI and the research team developed the New York University (NYU) Electronic Patient Visit Assessment (ePVA) for head and neck cancer (HNC) as a patient-reported outcome measure (PRO) for the early detection of uncontrolled symptoms. The ePVA is digital patient-reported symptom monitoring system, providing actionable information at point-of-care that enables clinicians to provide real-time interventions. The study aims to advance the science of cancer care delivery by testing the effectiveness of the ePVA as a digital patient-reported monitoring system for patients with HNC in real-world settings and identify implementation strategies that optimize the effectiveness of the ePVA in diverse rural and urban settings. The study hypothesis is that participants assigned to the ePVA arm will have better swallowing, taste and smell, and social function than participants assigned to usual care arm at 4 weeks after completing radiation therapy.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
270
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
NYU Electronic Patient Visit Assessment (ePVA) plus Usual CareUsual Care-
NYU Electronic Patient Visit Assessment (ePVA) plus Usual CareNYU Electronic Patient Visit Assessment (ePVA)-
Usual CareUsual Care-
Primary Outcome Measures
NameTimeMethod
Head and neck cancer (HNC) symptoms as assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)4 weeks after completing radiation therapy

The EORTC QLQ-C30 and QLQ-H\&N35 will be used to measure head and neck cancer symptoms, such as social function, senses of taste and smell, and swallowing. The scores will be summed and then transformed to a single score ranging from 0=Best to 100=Worst.

Secondary Outcome Measures
NameTimeMethod
Pain as assessed by EORTC QLQ-H&N35 Quality of Life Questionnaire (QLQ)4 weeks after completing radiation therapy

The EORTC QLQ-H\&N35 will be used to assess pain. The score will be summed and then transformed to a single score ranging from 0=Best to 100=Worst.

Health-Related Quality of Life (HRQoL) as assessed by the EORTC QLQ-C30 Quality of Life Questionnaire (QLQ)4 weeks after completing radiation therapy

The EORTC QLQ-H\&N35 will be used to assess Health-Related Quality of Life (HRQoL). The score will be summed and then transformed to a single score ranging from 0=Best to 100=Worst.

Acute Care Services Use as assessed by number of acute care visits4 weeks after completing radiation therapy

Acute Care Services Use is the use of services delivered in acute care settings, such as feeding tube placements, emergency room visits, and hospitalizations.

Acute Care Services Use as assessed by number of days of using acute care4 weeks after completing radiation therapy

Acute Care Services Use is the use of services delivered in acute care settings, such as feeding tube placements, emergency room visits, and hospitalizations.

Trial Locations

Locations (5)

NYU Meyers College of Nursing

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Fox Chase Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

NYU Langone Perlmutter Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

UTHealth Houston Cizik School of Nursing

๐Ÿ‡บ๐Ÿ‡ธ

Houston, Texas, United States

University of Kansas Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Kansas City, Kansas, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath